No Prescription |
 |
 | ||
|
RABICIP Aciphex |
|
| ||
No Prescription » Prescription Drugs 14 » RABICIP Aciphex Rabeprazole decreases the amount of acid produced in your stomach. Rabeprazole is used to treat ulcers gastroesophageal reflux disease (GERD or heartburn) and other conditions involving excessive stomach acid production. Rabeprazole treating heartburn or irritation of the esophagus caused by gastroesophageal reflux disease (GERD). It may be used for short-term treatment of ulcers of the small intestine. It may be used with certain antibiotics to treat ulcers of the small intestines and to help prevent them from coming back. It may be used to treat conditions that cause your body to make too much stomach acid (eg Zollinger-Ellison syndrome). It may also be used for other conditions as determined by your doctor.Rabeprazole is a proton pump inhibitor. It works by decreasing the amount of acid produced in the stomach. Buy RABICIP Aciphex and other Prescription Drugs 14 products online at Medstore. 3496
About RABICIP Aciphex: Product Type: Prescription Drugs 14 RABICIP ( Aciphex Generic Rabeprazole Sodium ) RABICIP (Aciphex Generic Rabeprazole Sodium) Aciphex Generic Rabeprazole Sodium 20mg 30 ( 3 x 10 ) Aciphex Generic Rabeprazole Sodium RABICIP
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
